Which Pharma Stock Stands Taller Right Now: LLY or PFE?
View original at finance.yahoo.comWhich Pharma Stock Stands Taller Right Now: LLY or PFE? Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product portfolios and robust R&D engines…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Loss of exclusivity cliff expected to hurt sales by approximately $1.5 billion in 2026
80% confidenceLilly is a clear winner over Pfizer due to exceptional growth from Mounjaro and Zepbound, product and pipeline portfolio in high-growth therapeutic areas like obesity, robust growth prospects and bullish analyst sentiment
80% confidenceMetsera candidates expected to generate billions of dollars in peak sales
80% confidenceNew and acquired products expected to deliver double-digit growth in 2026
80% confidencePfizer's 2026 EPS expected to decline 4.2% year-over-year
80% confidenceOrforglipron has potential to be approved and launched in 2026
80% confidenceCOVID revenues expected to be around $5 billion in 2026, $1.5 billion less than expected sales of about $6.5 billion in 2025
80% confidenceLilly's 2026 sales expected to increase 22.6% year-over-year
80% confidenceCost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027
80% confidencePfizer's 2026 sales expected to decline 2.1% year-over-year
80% confidenceMounjaro and Zepbound are expected to continue to see strong demand in 2026
80% confidenceData readouts from three phase III studies on retatrutide for treating obesity expected in the second half of 2026
80% confidenceLilly's 2026 EPS expected to increase 39.5% year-over-year
80% confidence